Navigation Links
Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes
Date:8/8/2014

urities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. 

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any notes, the guarantee or ordinary shares, nor shall there be any sale of notes, the guarantee or ordinary shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz® (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the U.S., including Erwinase® and Defitelio® (defibrotide).

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, all statements related to the offering of the notes, the guarantee and ordinary shares, including the closing thereof and the expected use of the net proceeds from the offering.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of eve
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
2. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
3. Access Pharmaceuticals Announces European License Agreement With Norgine
4. Vanda Pharmaceuticals Reports Second Quarter 2014 Results
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2014 Second Quarter Financial Results
6. AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.
7. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
8. Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes
9. Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
10. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
11. Jazz Pharmaceuticals Completes Acquisition Of Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... June 11, 2007-Sugammadex - the novel,selective relaxant binding ... business unit of Akzo Nobel - demonstrated in,a ... reversal of,neuromuscular blockade as compared to neostigmine, without ... of,muscle relaxation.1, 2 The results of this pivotal ...
... Md., June 11, 2007--A team of researchers at the,National ... (NIH), has uncovered a set of genes that are ... blood vessels that feed,tumors in mice and humans. These ... targets for novel drugs that,could selectively cut off a ...
Cached Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 2NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 3
(Date:5/22/2015)... May 22, 2015 Combination therapy, ... option for chronic obstructive pulmonary disorder (COPD) as ... and AstraZeneca plc as well as Germany’s Boehringer ... and position. But will market payers, clinicians and ... well-entrenched products to completely new ones? , In ...
(Date:5/22/2015)... Massachusetts (PRWEB) May 22, 2015 ... is a difficult process. Historically providers have not ... by payers. Starting in 2015, Medicare has paved ... coordination activities. Thanks to the launch of ... providers and health systems using the platform will ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... VA (PRWEB) May 22, 2015 sweetFrog Enterprises, ... location in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog ... yogurt chain was listed as #22 on the Inc. 500 ... “I have lived and worked in East Texas for 20 ... Brad Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog ...
(Date:5/22/2015)... In an effort to support the athletes of ... donate $5 dollars for every maintenance call, and $25 ... system. Customers have their needs serviced, and donations contributed ... the Special Olympics receives money. Hence the name Everybody ... million athletes, and boasts a myriad of events. This ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... May 21 This year 28 students in 17 states ... sponsored by the Centers for Disease Control and Prevention and ... invites fifth- and sixth-grade students to create posters that encourage ... and the diseases they can cause. Downloadable files of the ...
... 21 For the second year in a row, the ... blood through the Red Cross by joining Red Cross ... Racing is a program designed to increase the number ... Participants of this program can get points for a variety ...
... quarter of those seeking treatment are addicted to the ... -- More pregnant women in drug treatment programs are ... new research shows. , The number of expectant mothers ... 2006. In 1994, methamphetamine use accounted for 8 percent ...
... "Stem cell research and regenerative medicine are in an ... very fast and many companies are being formed and ... Jonas Frisn. , As an example, a first-in-human study ... drug product, sNN0031, from the Swedish company NeuroNova. The ...
... May 21 Three HealthEast hospitals in the ... the federal government a total of $2.28 million ... Medicare fraud involving a certain type of spinal ... first hospitals to settle charges stemming from a ...
... researchers have found that bipolar disorder is more costly ... or coronary artery disease. These findings are based on ... costs (the costs of seeing any specialist and all ... of this review are being presented today at the ...
Cached Medicine News:Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 2Health News:Methamphetamine Use Triples Among Pregnant Rehab Patients 3Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3
... glass (1.5x) Gonio lens will enable visualization ... 4 mirror lens is the industry preferred ... and features : , Crispest, clearest ... previously unattainable with Gonio lenses., 4 equally ...
Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
... to bulky biometry devices that have dominated ... is the world's only battery-operated, fully portable ... market today. Each unit weighs a mere ... multiple functions, namely: auto data capture, advanced ...
... The PalmScan P2000 Pachymeter [i.e., PalmScan ... portable,battery operated biometer, which incorporates A-mode ... used to accurately measure the corneal ... human eyes. PalmScan P2000 includes two ...
Medicine Products: